Last 12 months
Inside the activity.
0 purchase rows · 9 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2024 Filed Jan 9, 2024 22:26 UTC |
Wollin Robert JGENERAL COUNSEL AND SECRETARY
|
Exercise / conversionOrdinary Shares | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-000866 · form4-01092024_100139.xml · nonDerivative · entry 1 Wollin Robert J · CIK 0001815161 · GENERAL COUNSEL AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-half of restricted share units granted on January 7, 2022. F2 · price: Each restricted share unit converts into one ordinary share upon vesting. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:27 UTC |
Zeldin Robert KCHIEF MEDICAL OFFICER
|
Exercise / conversionRestricted Share Units · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000867 · form4-01092024_100116.xml · derivative · entry 3 Zeldin Robert K · CIK 0001745347 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F1 · derivative.exercise_date: Represents vesting of one-half of restricted share units granted on January 7, 2022. F1 · derivative.expiration_date: Represents vesting of one-half of restricted share units granted on January 7, 2022. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:27 UTC |
Zeldin Robert KCHIEF MEDICAL OFFICER
|
Tax withholdingOrdinary Shares | 18,507 | $6.30 | $116,594.10 |
DisclosureSEC source: 0001415889-24-000867 · form4-01092024_100116.xml · nonDerivative · entry 2 Zeldin Robert K · CIK 0001745347 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,980 F3 · shares: Shares withheld for payment of taxes upon vesting of award. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:27 UTC |
Zeldin Robert KCHIEF MEDICAL OFFICER
|
Exercise / conversionOrdinary Shares | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-000867 · form4-01092024_100116.xml · nonDerivative · entry 1 Zeldin Robert K · CIK 0001745347 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-half of restricted share units granted on January 7, 2022. F2 · price: Each restricted share unit converts into one ordinary share upon vesting. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:25 UTC |
Naylor StuartCHIEF DEV. OFFICER
|
Exercise / conversionRestricted Share Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000865 · form4-01092024_100151.xml · derivative · entry 5 Naylor Stuart · CIK 0001742771 · CHIEF DEV. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Ordinary Shares · 75,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F1 · derivative.exercise_date: Represents vesting of one-half of restricted share units granted on January 7, 2022. F1 · derivative.expiration_date: Represents vesting of one-half of restricted share units granted on January 7, 2022. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:25 UTC |
Naylor StuartCHIEF DEV. OFFICER
|
Tax withholdingOrdinary Shares | 35,250 | $6.30 | $222,075.00 |
DisclosureSEC source: 0001415889-24-000865 · form4-01092024_100151.xml · nonDerivative · entry 2 Naylor Stuart · CIK 0001742771 · CHIEF DEV. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,542 F3 · shares: Shares withheld for payment of taxes upon vesting of award. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:25 UTC |
Naylor StuartCHIEF DEV. OFFICER
|
Exercise / conversionOrdinary Shares | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-000865 · form4-01092024_100151.xml · nonDerivative · entry 1 Naylor Stuart · CIK 0001742771 · CHIEF DEV. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-half of restricted share units granted on January 7, 2022. F2 · price: Each restricted share unit converts into one ordinary share upon vesting. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:25 UTC |
Giroux RichardCFO & COO
|
Exercise / conversionRestricted Share Units · Derivative | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000864 · form4-01092024_100155.xml · derivative · entry 7 Giroux Richard · CIK 0001742734 · CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Ordinary Shares · 105,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F1 · derivative.exercise_date: Represents vesting of one-half of restricted share units granted on January 7, 2022. F1 · derivative.expiration_date: Represents vesting of one-half of restricted share units granted on January 7, 2022. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:25 UTC |
Giroux RichardCFO & COO
|
Tax withholdingOrdinary Shares | 55,520 | $6.30 | $349,776.00 |
DisclosureSEC source: 0001415889-24-000864 · form4-01092024_100155.xml · nonDerivative · entry 2 Giroux Richard · CIK 0001742734 · CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 824,474 F3 · shares: Shares withheld for payment of taxes upon vesting of award. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:25 UTC |
Giroux RichardCFO & COO
|
Exercise / conversionOrdinary Shares | 105,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-000864 · form4-01092024_100155.xml · nonDerivative · entry 1 Giroux Richard · CIK 0001742734 · CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 879,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-half of restricted share units granted on January 7, 2022. F2 · price: Each restricted share unit converts into one ordinary share upon vesting. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:23 UTC |
Forbes AlexandriaDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Share Units · Derivative | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000863 · form4-01092024_100141.xml · derivative · entry 6 Forbes Alexandria · CIK 0001678604 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Ordinary Shares · 125,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F1 · derivative.exercise_date: Represents vesting of one-half of restricted share units granted on January 7, 2022. F1 · derivative.expiration_date: Represents vesting of one-half of restricted share units granted on January 7, 2022. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:23 UTC |
Forbes AlexandriaDirector · PRESIDENT & CEO
|
Tax withholdingOrdinary Shares | 66,095 | $6.30 | $416,398.50 |
DisclosureSEC source: 0001415889-24-000863 · form4-01092024_100141.xml · nonDerivative · entry 2 Forbes Alexandria · CIK 0001678604 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,338,394 F5 · shares: Shares withheld for payment of taxes upon vesting of award. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 22:23 UTC |
Forbes AlexandriaDirector · PRESIDENT & CEO
|
Exercise / conversionOrdinary Shares | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-000863 · form4-01092024_100141.xml · nonDerivative · entry 1 Forbes Alexandria · CIK 0001678604 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,404,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-half of restricted share units granted on January 7, 2022. F2 · price: Each restricted share unit converts into one ordinary share upon vesting. F3 · balance_after: On July 14, 2023, in a transaction exempt from Section 16 (including the reporting requirements) by virtue of Rule 16a-13, the reporting person received 27,024 ordinary shares as an annuity payment from a grantor retained annuity trust ("GRAT") and now reports "direct" beneficial ownership of those shares. F4 · balance_after: On August 11, 2023, in a transaction exempt from Section 16 (including the reporting requirements) by virtue of Rule 16a-13, the reporting person received 146,015 ordinary shares as an annuity payment from a second grantor retained annuity trust ("GRAT") and now reports "direct" beneficial ownership of those shares. Read SEC document |
| January 07, 2024 Filed Jan 18, 2024 22:17 UTC Amendment |
Zeldin Robert KCHIEF MEDICAL OFFICER
|
Tax withholdingOrdinary Shares | 13,773 | $6.30 | $86,769.90 |
DisclosureSEC source: 0001415889-24-001527 · form4a-01182024_100113.xml · nonDerivative · entry 1 Zeldin Robert K · CIK 0001745347 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,714 F1 · shares: Shares withheld for payment of taxes upon vesting of award. F2 · shares: Due to an administrative error, this Form 4 is being amended to reflect the correct number of shares being withheld for payment of taxes as well as the number of securities beneficially owned following the reported transaction. F2 · balance_after: Due to an administrative error, this Form 4 is being amended to reflect the correct number of shares being withheld for payment of taxes as well as the number of securities beneficially owned following the reported transaction. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 13:36 UTC | OtherOrdinary Shares | 6,641,064 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019202 · doc4.xml · nonDerivative · entry 1 Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · price: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · balance_after: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · ownership.direct: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. Read SEC document |
|
| June 08, 2023 Filed Jun 9, 2023 12:48 UTC |
Mendoza NeilDirector
|
GrantRestricted Share Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009472 · form4-06092023_120625.xml · derivative · entry 2 Mendoza Neil · CIK 0001742502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F3 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. F3 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 12:48 UTC |
Mendoza NeilDirector
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001415889-23-009472 · form4-06092023_120625.xml · derivative · entry 1 Mendoza Neil · CIK 0001742502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 12:50 UTC |
SHENK THOMAS EDirector
|
GrantRestricted Share Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009474 · form4-06092023_120650.xml · derivative · entry 2 SHENK THOMAS E · CIK 0001204362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F3 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. F3 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 12:50 UTC |
SHENK THOMAS EDirector
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001415889-23-009474 · form4-06092023_120650.xml · derivative · entry 1 SHENK THOMAS E · CIK 0001204362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 12:49 UTC |
Seligman NicoleDirector
|
GrantRestricted Share Units · Derivative | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009473 · form4-06092023_120627.xml · derivative · entry 2 Seligman Nicole · CIK 0001683100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Ordinary Shares · 22,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F3 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. F3 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 12:49 UTC |
Seligman NicoleDirector
|
GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001415889-23-009473 · form4-06092023_120627.xml · derivative · entry 1 Seligman Nicole · CIK 0001683100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Ordinary Shares · 22,500 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 12:47 UTC |
Hukkelhoven EllenDirector
|
GrantRestricted Share Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009471 · form4-06092023_120655.xml · derivative · entry 2 Hukkelhoven Ellen · CIK 0001743337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F3 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. F3 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 12:47 UTC |
Hukkelhoven EllenDirector
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001415889-23-009471 · form4-06092023_120655.xml · derivative · entry 1 Hukkelhoven Ellen · CIK 0001743337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 12:46 UTC |
Indyk MartinDirector
|
GrantRestricted Share Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009470 · form4-06092023_120645.xml · derivative · entry 4 Indyk Martin · CIK 0001766997 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F4 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. F4 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 12:46 UTC |
Indyk MartinDirector
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001415889-23-009470 · form4-06092023_120645.xml · derivative · entry 3 Indyk Martin · CIK 0001766997 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2033-06-08 F3 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 12:46 UTC |
Harris Keith R.Director
|
GrantRestricted Share Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009469 · form4-06092023_120601.xml · derivative · entry 4 Harris Keith R. · CIK 0001742703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F4 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. F4 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 12:46 UTC |
Harris Keith R.Director
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001415889-23-009469 · form4-06092023_120601.xml · derivative · entry 3 Harris Keith R. · CIK 0001742703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2033-06-08 F3 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:07 UTC |
PERCEPTIVE ADVISORS LLCDirector · 10% owner
PERCEPTIVE LIFE SCIENCES MASTER FUND LTDDirector · 10% owner
EDELMAN JOSEPHDirector · 10% owner
|
GrantRestricted Share Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-013340 · form4.xml · derivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share of the Issuer upon settlement. The restricted share units become settleable when Ellen Hukkelhoven ("Ms. Hukkelhoven") ceases to be a director of the Issuer. F3 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. F3 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. F4 · ownership.nature: Ms. Hukkelhoven is a Managing Director of Perceptive Advisors, LLC (the "Advisor"). The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor may be deemed to have an indirect pecuniary interest in the securities reported herein because the Advisor has the right to receive the director compensation provided in respect of Ms. Hukkelhoven's board service through a partial management fee offset. Joseph Edelman ("Mr. Edelman") is the managing member of the Advisor. Each of Mr. Edelman, the Master Fund and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman, the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:07 UTC |
PERCEPTIVE ADVISORS LLCDirector · 10% owner
PERCEPTIVE LIFE SCIENCES MASTER FUND LTDDirector · 10% owner
EDELMAN JOSEPHDirector · 10% owner
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001062993-23-013340 · form4.xml · derivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earliest of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. F4 · ownership.nature: Ms. Hukkelhoven is a Managing Director of Perceptive Advisors, LLC (the "Advisor"). The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor may be deemed to have an indirect pecuniary interest in the securities reported herein because the Advisor has the right to receive the director compensation provided in respect of Ms. Hukkelhoven's board service through a partial management fee offset. Joseph Edelman ("Mr. Edelman") is the managing member of the Advisor. Each of Mr. Edelman, the Master Fund and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman, the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:27 UTC |
Yu DebraDirector
|
GrantRestricted Share Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009616 · form4-06122023_080644.xml · derivative · entry 2 Yu Debra · CIK 0001869480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F3 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. F3 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:27 UTC |
Yu DebraDirector
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001415889-23-009616 · form4-06122023_080644.xml · derivative · entry 1 Yu Debra · CIK 0001869480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 12:46 UTC |
Indyk MartinDirector
|
Exercise / conversionRestricted Share Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009470 · form4-06092023_120645.xml · derivative · entry 2 Indyk Martin · CIK 0001766997 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F2 · derivative.exercise_date: The restricted share units vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. F2 · derivative.expiration_date: The restricted share units vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 12:46 UTC |
Indyk MartinDirector
|
Exercise / conversionOrdinary Shares | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-009470 · form4-06092023_120645.xml · nonDerivative · entry 1 Indyk Martin · CIK 0001766997 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted share unit converts into one ordinary share upon vesting. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 12:46 UTC |
Harris Keith R.Director
|
Exercise / conversionRestricted Share Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009469 · form4-06092023_120601.xml · derivative · entry 2 Harris Keith R. · CIK 0001742703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F2 · derivative.exercise_date: The restricted share units vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. F2 · derivative.expiration_date: The restricted share units vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 12:46 UTC |
Harris Keith R.Director
|
Exercise / conversionOrdinary Shares | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-009469 · form4-06092023_120601.xml · nonDerivative · entry 1 Harris Keith R. · CIK 0001742703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted share unit converts into one ordinary share upon vesting. Read SEC document |
| May 05, 2023 Filed May 16, 2023 00:12 UTC |
PERCEPTIVE ADVISORS LLCDirector · 10% owner
EDELMAN JOSEPH10% owner
|
PurchaseOrdinary Shares | 4,347,826 | $5.75 | $24,999,999.50 |
DisclosureSEC source: 0000899243-23-013015 · doc4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 11,281,103 F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:58 UTC |
Wollin Robert JGENERAL COUNSEL AND SECRETARY
|
GrantRestricted Share Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003198 · form4-02232023_090218.xml · derivative · entry 2 Wollin Robert J · CIK 0001815161 · GENERAL COUNSEL AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F3 · derivative.exercise_date: Fifty percent of the restricted share unit award will vest on the second anniversary of the grant date and twenty-five percent of the restricted share unit award will vest on each of the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Fifty percent of the restricted share unit award will vest on the second anniversary of the grant date and twenty-five percent of the restricted share unit award will vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:58 UTC |
Wollin Robert JGENERAL COUNSEL AND SECRETARY
|
GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001415889-23-003198 · form4-02232023_090218.xml · derivative · entry 1 Wollin Robert J · CIK 0001815161 · GENERAL COUNSEL AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: The option vests as to one quarter of the total grant on February 21, 2024 and vests as to the remainder in 36 equal monthly installments thereafter. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:59 UTC |
Zeldin Robert KCHIEF MEDICAL OFFICER
|
GrantRestricted Share Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003199 · form4-02232023_090215.xml · derivative · entry 2 Zeldin Robert K · CIK 0001745347 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F3 · derivative.exercise_date: Fifty percent of the restricted share unit award will vest on the second anniversary of the grant date and twenty-five percent of the restricted share unit award will vest on each of the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Fifty percent of the restricted share unit award will vest on the second anniversary of the grant date and twenty-five percent of the restricted share unit award will vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:59 UTC |
Zeldin Robert KCHIEF MEDICAL OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001415889-23-003199 · form4-02232023_090215.xml · derivative · entry 1 Zeldin Robert K · CIK 0001745347 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: The option vests as to one quarter of the total grant on February 21, 2024 and vests as to the remainder in 36 equal monthly installments thereafter. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:56 UTC |
Naylor StuartCHIEF DEV. OFFICER
|
GrantRestricted Share Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003197 · form4-02232023_090257.xml · derivative · entry 2 Naylor Stuart · CIK 0001742771 · CHIEF DEV. OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F3 · derivative.exercise_date: Fifty percent of the restricted share unit award will vest on the second anniversary of the grant date and twenty-five percent of the restricted share unit award will vest on each of the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Fifty percent of the restricted share unit award will vest on the second anniversary of the grant date and twenty-five percent of the restricted share unit award will vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:56 UTC |
Naylor StuartCHIEF DEV. OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001415889-23-003197 · form4-02232023_090257.xml · derivative · entry 1 Naylor Stuart · CIK 0001742771 · CHIEF DEV. OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: The option vests as to one quarter of the total grant on February 21, 2024 and vests as to the remainder in 36 equal monthly installments thereafter. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:53 UTC |
Forbes AlexandriaDirector · PRESIDENT & CEO
|
GrantRestricted Share Units · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003193 · form4-02232023_090238.xml · derivative · entry 2 Forbes Alexandria · CIK 0001678604 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Ordinary Shares · 250,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F3 · derivative.exercise_date: Fifty percent of the restricted share unit award will vest on the second anniversary of the grant date and twenty-five percent of the restricted share unit award will vest on each of the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Fifty percent of the restricted share unit award will vest on the second anniversary of the grant date and twenty-five percent of the restricted share unit award will vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:53 UTC |
Forbes AlexandriaDirector · PRESIDENT & CEO
|
GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001415889-23-003193 · form4-02232023_090238.xml · derivative · entry 1 Forbes Alexandria · CIK 0001678604 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Ordinary Shares · 225,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: The option vests as to one quarter of the total grant on February 21, 2024 and vests as to the remainder in 36 equal monthly installments thereafter. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:54 UTC |
Giroux RichardCFO & COO
|
GrantRestricted Share Units · Derivative | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003195 · form4-02232023_090211.xml · derivative · entry 2 Giroux Richard · CIK 0001742734 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Ordinary Shares · 240,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F3 · derivative.exercise_date: Fifty percent of the restricted share unit award will vest on the second anniversary of the grant date and twenty-five percent of the restricted share unit award will vest on each of the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Fifty percent of the restricted share unit award will vest on the second anniversary of the grant date and twenty-five percent of the restricted share unit award will vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:54 UTC |
Giroux RichardCFO & COO
|
GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001415889-23-003195 · form4-02232023_090211.xml · derivative · entry 1 Giroux Richard · CIK 0001742734 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Ordinary Shares · 135,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: The option vests as to one quarter of the total grant on February 21, 2024 and vests as to the remainder in 36 equal monthly installments thereafter. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 22:04 UTC |
Wollin Robert JGENERAL COUNSEL AND SECRETARY
|
Exercise / conversionRestricted Share Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-001088 · form4-01182023_100125.xml · derivative · entry 3 Wollin Robert J · CIK 0001815161 · GENERAL COUNSEL AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F1 · derivative.exercise_date: Represents vesting of one-half of restricted share units granted on January 14, 2021. F1 · derivative.expiration_date: Represents vesting of one-half of restricted share units granted on January 14, 2021. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 22:04 UTC |
Wollin Robert JGENERAL COUNSEL AND SECRETARY
|
Tax withholdingOrdinary Shares | 5,288 | $6.99 | $36,963.12 |
DisclosureSEC source: 0001415889-23-001088 · form4-01182023_100125.xml · nonDerivative · entry 2 Wollin Robert J · CIK 0001815161 · GENERAL COUNSEL AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,712 F3 · shares: Shares withheld for payment of taxes upon vesting of award. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 22:04 UTC |
Wollin Robert JGENERAL COUNSEL AND SECRETARY
|
Exercise / conversionOrdinary Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-001088 · form4-01182023_100125.xml · nonDerivative · entry 1 Wollin Robert J · CIK 0001815161 · GENERAL COUNSEL AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-half of restricted share units granted on January 14, 2021. F2 · price: Each restricted share unit converts into one ordinary share upon vesting. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 21:59 UTC |
Giroux RichardCFO & COO
|
Exercise / conversionRestricted Share Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-001082 · form4-01182023_090144.xml · derivative · entry 6 Giroux Richard · CIK 0001742734 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F1 · derivative.exercise_date: Represents vesting of one-half of restricted share units granted on January 14, 2021. F1 · derivative.expiration_date: Represents vesting of one-half of restricted share units granted on January 14, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.